Halozyme Therapeutics Earnings: Here’s Why Investors are Not Happy Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Halozyme Therapeutics, Inc. (NASDAQ:HALO) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 1.28%.

Halozyme Therapeutics, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.2 in the quarter versus EPS of $-0.13 in the year-earlier quarter.

Revenue: Rose 87.24% to $14.53 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Halozyme Therapeutics, Inc. reported adjusted EPS loss of $0.2 per share. By that measure, the company missed the mean analyst estimate of $-0.13. It beat the average revenue estimate of $11.29 million.

Quoting Management: “Significant regulatory milestones were achieved with Baxter’s HyQvia and Roche’s Herceptin last quarter. Working with our partners, we look forward to bringing these life-changing treatments to patients and medical communities across Europe,” said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. “We also announced clinical advancement of our proprietary programs in pancreatic cancer, diabetes and dermatology, further accelerating our key value drivers enabled by our technology platform.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business